Magforce AG
XETRA:MF6
Intrinsic Value
MagForce AG engages in the development and distribution of a nanotechnology based cancer therapy. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of MF6.
Fundamental Analysis
Balance Sheet Decomposition
Magforce AG
Current Assets | 1.3m |
Cash & Short-Term Investments | 114.7k |
Receivables | 736.1k |
Other Current Assets | 460.1k |
Non-Current Assets | 61.5m |
Long-Term Investments | 56.6m |
PP&E | 3m |
Intangibles | 1.6m |
Other Non-Current Assets | 412.6k |
Current Liabilities | 33.8m |
Accounts Payable | 648k |
Accrued Liabilities | 71.7k |
Short-Term Debt | 8.9m |
Other Current Liabilities | 24.2m |
Non-Current Liabilities | 2.2m |
Other Non-Current Liabilities | 2.2m |
Earnings Waterfall
Magforce AG
Revenue
|
352k
EUR
|
Cost of Revenue
|
-668.6k
EUR
|
Gross Profit
|
-316.6k
EUR
|
Operating Expenses
|
-6m
EUR
|
Operating Income
|
-6.3m
EUR
|
Other Expenses
|
-4.3m
EUR
|
Net Income
|
-10.6m
EUR
|
Free Cash Flow Analysis
Magforce AG
MF6 Profitability Score
Profitability Due Diligence
Magforce AG's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Magforce AG's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
MF6 Solvency Score
Solvency Due Diligence
Magforce AG's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Magforce AG's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MF6 Price Targets Summary
Magforce AG
Shareholder Return
MF6 Price
Magforce AG
Average Annual Return | 5.37% |
Standard Deviation of Annual Returns | 24.42% |
Max Drawdown | -99% |
Market Capitalization | 2.4m EUR |
Shares Outstanding | 29 462 500 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MagForce AG engages in the development and distribution of a nanotechnology based cancer therapy. The company is headquartered in Berlin, Berlin and currently employs 67 full-time employees. The company went IPO on 2007-09-21. Its non-invasive technology uses magnetic nanoparticles to combat tumors, without harmful effect on the healthy tissues. The firm's range of treatment products includes NanoTherm Therapie for treating tumors locally; NanoTherm, a fluid containing ferrous oxide molecules that penetrate deeply into the tumor tissues and reacting to the presence of a magnetic field; NanoActivator, which are iron oxide nanoparticles for tumors in all areas of the body, and NanoPlan, a software platform that facilitates therapy planning and adjusts proper temperatures for the treatment and and the necessary magnetic field strength. As of December 31, 2011, Nanostart AG held a 49.6%-stake in the Company.